Generic drugmaker Endo posts quarterly loss due to charge

Aug 8 (Reuters) - Generic drugmaker Endo International Plc reported a quarterly loss versus a profit a year earlier, hurt mainly by impairment charges of $725 million.

The Dublin, Ireland-based drugmaker's net loss from continuing operations was $696 million, or $3.12 per share, in the second quarter ended June 30, from a profit of $389.8 million, or $1.75 per share, a year earlier.

Total revenue fell 4.9 percent to $875.7 million. (Reporting by Akankshita Mukhopadhyay and Manas Mishra in Bengaluru; Editing by Martina D'Couto)